Company Overview
Snapshot
Founded in January 1941 by David Fuhrer, Neopharm Group operates with 51–200 employees. In November 2025, the company expanded its Israeli distribution capabilities through its subsidiary Eldan, following an investment in FIZE Medical.
Business overview
Neopharm Group is a family of companies focused on the research, development, manufacturing, marketing, sales, and distribution of healthcare products across more than 60 countries. The company operates in three primary segments: pharmaceutical, consumer healthcare, and medical devices, serving the broader Health Tech & Life Sciences sector.
Strategic signal
In November 2025, Neopharm Group's subsidiary Eldan facilitated an investment in FIZE Medical, a leader in smart fluid management solutions, and expanded its Israeli distribution. This move signals Neopharm's strategic intent to enhance its medical device portfolio and strengthen its market presence in critical care solutions, indicating a focus on innovation and market expansion within the healthcare sector.
Log in to access full profile ›Company Intelligence Q&A
- What was a significant recent strategic development for Neopharm Group?
- In November 2025, Neopharm Group's subsidiary Eldan expanded its Israeli distribution network and participated in an investment round for FIZE Medical, a company specializing in smart fluid management solutions for critically ill patients.
- When was Neopharm Group founded?
- Neopharm Group was founded in January 1941.
- Who is the founder of Neopharm Group?
- David Fuhrer is the founder, owner, chairman, and CEO of Neopharm Group.
- What is Neopharm Group's primary business focus?
- Neopharm Group engages in the research, development, manufacturing, marketing, sales, and distribution of a wide range of products within the pharmaceutical, consumer healthcare, and medical devices segments.
- What was a key partnership for Neopharm Group in March 2023?
- In March 2023, Neopharm Group signed a license agreement with Amylyx for an ALS therapy, expanding its pharmaceutical offerings.